BRIEF published on 05/11/2026 at 08:05, 1 month 15 days ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE published on 05/11/2026 at 08:00, 1 month 15 days ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 1 month 19 days ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 1 month 19 days ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 1 month 19 days ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 2 months 26 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 2 months 26 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 2 months 26 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 3 months 7 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
BRIEF published on 03/19/2026 at 10:19, 3 months 7 days ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
Published on 06/26/2026 at 01:40, 9 hours 6 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 11 hours 16 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 12 hours 16 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 13 hours 14 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 19 hours 16 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 10:30, 16 minutes ago Uniper and Skyborn Renewables sign offshore wind PPA
Published on 06/26/2026 at 10:25, 20 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Initial Sale Prices
Published on 06/26/2026 at 10:25, 20 minutes ago Beijing Art Season 2026 Concludes with Record Public Engagement
Published on 06/26/2026 at 10:15, 30 minutes ago FP Markets expands its share CFD portfolio with landmark SpaceX (SPCX) listing
Published on 06/26/2026 at 10:00, 46 minutes ago Europe and China Must Pivot from Tech Rivalry to 'Constructive Engagement' in AI Era, Warn Leaders at CEIBS Forums
Published on 06/26/2026 at 07:00, 3 hours 46 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 3 hours 46 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 16 hours 1 minute ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 16 hours 16 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 16 hours 56 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
